Cited by 38Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 239 of the 242 references it cites were found in a registry or an index.

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

Open access

Arredouani, Abdelilah·2025·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2025.108824

Open this paper in CoChat — free account

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of metabolic disorders, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds are not only well-established in the treatment of type 2 diabetes (T2D) and obesity-conditions for which they have received widespread approval-but also exhibit promising potential in addressing cardiovascular disease (CVD) and Metabolic dysfunction-associated steatotic liver disease (MASLD). Recent investigations have begun to illuminate the utility of GLP-1RAs in the management of type 1 diabetes (T1D), as well as neurodegenerative disorders such as Alzheimer's and Parkinson's disease and various behavioral disorders. A plethora of clinical trials have consistently validated the capacity of GLP-1RAs to improve glycemic control, promote weight loss, and mitigate cardiovascular risk factors in individuals with T2D and obesity. While their application in T1D remains limited due to safety concerns-particularly regarding the risks of hypoglycemia and hyperglycemic ketoacidosis-emerging data suggest that GLP-1RAs may offer hepatoprotective benefits, potentially reducing liver fat content and decelerating the progression of MASLD. The neuroprotective attributes of GLP-1 RAs have garnered significant interest, with research indicating their potential to alleviate cognitive decline associated with neurodegenerative diseases. Furthermore, preliminary findings highlight the role of GLP-1 RAs in addressing behavioral disorders, emphasizing their extensive therapeutic promise. This comprehensive review synthesizes the current evidence supporting the diverse therapeutic applications of GLP-1RAs, positioning them as "magic drug" therapies for metabolic and neurological disorders. As ongoing research continues to explore innovative applications and combinations of GLP-1RAs, the landscape of disease management in metabolic and neurological contexts is poised for transformative advancements. This review will also critically assess safety considerations and underscore the need for personalized treatment strategies to optimize patient outcomes in these complex and often comorbid conditions.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2025.108824

Cites

239 of 239 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Items 201–239 of 239

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
Nauck, M. A., Walberg, J., Vethacke, A., El-Ouaghlidi, A., Senkal, M., Holst, J. J., Gallwitz, J. B., Schmidt, W. E., & Schmiegel, W. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.11.003 · Cited by 46
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes
Pozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
Use of incretin agents and risk of pancreatic cancer: a population‐based cohort study
Knapen, L. M., Dalem, J. D. R.-V., Keulemans, Y. C. A., van Erp, N. P., Bazelier, M. T., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12605 · Cited by 45
GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A
Dai, Y., Dai, D., Wang, X., Ding, Z., Li, C., & Mehta, J. L. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000087 · Cited by 45
Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis
Gharagozloo, M., Smith, M. D., Sotirchos, E. S., Jin, J., Meyers, K. R., Taylor, M., Garton, T. P., Bannon, R. N., Lord, H., Dawson, T. M., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01088-5 · Cited by 45
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold, K. C., Reynolds, J., Dziura, J. D., Baidal, D. A., Gaglia, J. L., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14121 · Cited by 44
GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor
Fusco, J. C., Xiao, X., Prasadan, K. L., Sheng, Q., Chen, C., Ming, Y.-C., & Gittes, G. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-09898-4 · Cited by 43
Exendin-4 promotes the vascular smooth muscle cell re-differentiation through AMPK/SIRT1/FOXO3a signaling pathways
Liu, Z., Zhang, M., Zhou, T., Shen, Q., & Qin, X. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.016 · Cited by 43
GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling
Chang, C., Lin, T.-C., Ho, H.-L., Kuo, C.-Y., Li, H., Короленко, Т. А., Chen, W. J., Lai, T., Ho, Y., & Lin, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092505 · Cited by 43
Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
Khalifa, O., Al-Akl, N. S., Errafii‬, K., & Arredouani, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06143-5 · Cited by 43
Self-citation
Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature
Salazar, C. E., Patil, M. K., Aihie, O., Cruz, N., & Nambudiri, V. E. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-02969-3 · Cited by 43
Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects
Tanaka, M., Matsuo, Y., Yamakage, H., Masuda, S., Terada, Y., Muranaka, K., Wada, H., Hasegawa, K., Shimatsu, A., & Satoh‐Asahara, N. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.009 · Cited by 41
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial
Wang, W., Bain, S. C., Bian, F., Chen, R., Gabery, S., Huang, S., Jensen, T. B., Luo, B., Yuan, G., Ning, G., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06142-3 · Cited by 37
Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice
Tsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y. (2019) · Cells · doi:10.3390/cells8060589 · Cited by 37
Incretin-based drugs and intestinal obstruction: A pharmacovigilance study
Gudin, B., Ladhari, C., Robin, P., Laroche, M.-L., Babai, S., Hillaire-Buys, D., & Faillie, J.-L. (2020) · Therapies · doi:10.1016/j.therap.2020.02.024 · Cited by 37
Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
Yokomori, H., & Ando, W. (2020) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2019-000370 · Cited by 35
Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation
Li, A. Q., Zhao, L., Zhou, T. F., Zhang, M. Q., & Qin, X. M. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00249.2014 · Cited by 33
The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis
Lomeli, L. D., Kodali, A. M., Tsushima, Y., Mehta, A., & Pantalone, K. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111806 · Cited by 32
Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling
Lee, J., Hong, S., Kim, M.-J., Kwon, H., Park, S. E., Rhee, E., & Lee, W. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.136 · Cited by 31
Exenatide-Induced Chronic Damage of Pancreatic Tissue in Rats
Yu, X., Huayong, T., Huang, L., Yang, Y., Tian, B., & Yu, C. (2012) · Pancreas · doi:10.1097/mpa.0b013e31824e67a3 · Cited by 30
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway
Fan, S., Xiong, Q., Wang, L., Zhang, L., & Shi, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111005 · Cited by 30
A systematic review and meta‐analysis of observational studies of the association between the use of incretin‐based therapies and the risk of pancreatic cancer
Hidayat, K., Zhou, Y., Du, H., Qin, L., Shi, B., & Li, Z. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5550 · Cited by 30
Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1β/CXCR7–AMPK/p38-MAPK/IL-6 axis
Yang, Y. H., Zhou, Y., Wang, Y., Wei, X., Wu, L., Wang, T., & Ma, A. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01551-3 · Cited by 28
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial
Ji, L., Agesen, R. M., Bain, S. C., Fu, F., Gabery, S., Geng, J., Li, Y., Lu, Y., Luo, B., Pang, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06133-4 · Cited by 26
Pancreatitis with Pancreatic Tail Swelling Associated with Incretin-based Therapies Detected Radiologically in Two Cases of Diabetic Patients with End-Stage Renal Disease
Nakata, H., Sugitani, S., Yamaji, S., Otsu, S., Higashi, Y., Ohtomo, Y., & Inoue, G. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.7876 · Cited by 25
Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study
Philis‐Tsimikas, A., Wysham, C., Hardy, E., Han, J., & Iqbal, N. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.012 · Cited by 25
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 24
Effect of combination pioglitazone with sodium‐glucose cotransporter‐2 inhibitors or glucagon‐like peptide ‐1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta‐analysis, and real‐world study from an international federated database
Anson, M., Henney, A. E., Zhao, S. S., Hernández, G., Lip, G. Y. H., Cuthbertson, D. J., Nabrdalik, K., & Alam, U. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15576 · Cited by 21
Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial
Krychtiuk, K. A., Marquis‐Gravel, G., Murphy, S., Alexander, K. P., Chiswell, K., Green, J. B., Leiter, L. A., Lópes, R. D., Prato, S. D., Jones, W. S., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae006 · Cited by 21
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program
Kim, D. D., Hwang, J. H., & Fendrick, A. M. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae055 · Cited by 21
Addition of glucagon‐like peptide‐1 receptor agonist therapy to insulin in C‐peptide‐positive patients with type 1 diabetes
Kuhadiya, N. D., Prohaska, B. D., Ghanim, H., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13609 · Cited by 18
Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss
Udawatta, M., Fidalgo, N., & Mateen, F. J. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07701-7 · Cited by 15
Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial
Thivolet, C. H., Larger, É., Cariou, B., Renard, É., Hanaire, H. P., Benhamou, P., Guerci, B., Mathiotte, É., & Chikh, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101433 · Cited by 13
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD ‐11 trial
Frías, J. P., Bonora, E., Ruiz, L. N., Hsia, S. H., Jung, H., Raha, S., Cox, D. A., Bethel, M. A., & Кониг, М. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14469 · Cited by 11
Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world
Franch‐Nadal, J., Granado-Casas, M., Mata‐Cases, M., Ortega, E., Vlacho, B., & Mauricio, D. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.10.005 · Cited by 11
GLP-1 signaling and the regulation of pancreatic β-cells mass/function
Buteau, J. (2011) · Avances en Diabetología · doi:10.1016/s1134-3230(11)70002-3 · Cited by 10
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
Escobar, C. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00183-9 · Cited by 10
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD ‐11
Frías, J. P., Bonora, E., Cox, D. A., Bethel, M. A., Kwan, A. Y. M., Raha, S., & Malik, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14533 · Cited by 7

Research works printed but not linked: 8

Administration, 2021, vol. 2024
Azoulay, 2016, Ernst P, Canadian Network for Observational Drug Effect Studies Investigators. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ., 352, i581
Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor, Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 · DOI
Wang, 2015, Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway, J Geriatr Cardiol, 12, 410
Wang, 2024, Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes, JAMA Netw Open, 7, 10.1001/jamanetworkopen.2024.21305 · DOI · Paper page
Yang, 2020, Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1β/CXCR7-AMPK/p38-MAPK/IL-6 axis, Acta Diabetol, 57, 1315, 10.1007/s00592-020-01551-3 · DOI
Yang, 2021, Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis, Mediators Inflamm., 2021 Mar 27, 5568159
Zeng, 2023, Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 14, 1214334, 10.3389/fendo.2023.1214334 · DOI · Paper page

Sorted by citations

Gut–Brain Axis and Bile Acid Signaling: Linking Microbial Metabolism to Brain Function and Metabolic Regulation
Stanimirov, B., Đanić, M., Pavlović, N., Zaklan, D., Lazarević, S., Mikov, M., & Stankov, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412167 · Cited by 39
Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
Cedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 25
GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101708 · Cited by 21
Cardiovascular disease and depression: a bidirectional relationship and its clinical implications
Wu, J., Tian, Z., Qi, Z., Liu, X., & Yu, P. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1675680 · Cited by 14
The evolving landscape of pharmacogenomics: Current achievements and future directions
Lauschke, V. M., & Ingelman‐Sundberg, M. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100122 · Cited by 13

See all 38

Authors: Arredouani, A.
Affiliations: Hamad bin Khalifa University (QA)
Corresponding author: Arredouani, Abdelilah
ORCID: Arredouani, Abdelilah
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2025-05
Volume: 269
Pages: 108824
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2025.108824
OpenAlex: W4407723359
Cited by: 36
References: 242
Citations by year: 2026: 23 · 2025: 13
FWCI: 4.93
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 21 d)
Locations: Pharmacology & Therapeutics (publishedVersion, cc-by)
PubMed (publishedVersion)
Figshare (submittedVersion, cc-by)
Funders: Hamad Bin Khalifa University Qatar Biomedical Research Institute
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: GLP-1 receptor agonists, type 2 diabetes, obesity, type 1 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, cognitive decline, hepatoprotection, weight loss, glycemic control, hypoglycemia, behavioral disorders, personalized treatment
MeSH terms: Glucagon-Like Peptide-1 Receptor Agonists, Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metabolic Diseases, Obesity, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks